碳酸司维拉姆对CKD患者血清Klotho和FGF23影响的随机临床试验
这项双盲安慰剂对照随机多中心研究纳入78例血磷正常、eGFR 15-45 ml/min/1.73 m²且血清C端FGF23>80 RU/ml的CKD 3b/4期患者,随机接受碳酸司维拉姆4.8 g/日或安慰剂治疗12周,所有患者随机时接受100,000 IU胆钙化醇。结果显示司维拉姆显著降低尿磷/肌酐比值和血清总胆固醇及LDL胆固醇,但未显著改变血清C端FGF23、完整FGF23或α-Klotho水平。
要点
- 碳酸司维拉姆12周治疗显著降低CKD患者尿磷排泄,但不改变血磷。
- 司维拉姆未显著影响血清C端FGF23、完整FGF23或α-Klotho水平。
- 司维拉姆显著降低血清总胆固醇和LDL胆固醇。
核心结论
- 在血磷正常的CKD 3b/4期患者中,碳酸司维拉姆治疗12周显著降低尿磷排泄,但未显著改变血清C端FGF23、完整FGF23或α-Klotho水平。
研究设计与样本
- 双盲、安慰剂对照、随机多中心研究纳入78例CKD患者,平均年龄63±13岁,70%为男性,平均eGFR 27±9 ml/min/1.73 m²。
- 纳入标准为eGFR 45-15 ml/min/1.73 m²、空腹血磷>3.1 mg/dl、血清C端FGF23>80 RU/ml;所有患者随机时接受100,000 IU胆钙化醇。
- 患者随机接受安慰剂或碳酸司维拉姆4.8 g/日治疗12周,基线和12周评估血清C端FGF23、完整FGF23和α-Klotho等指标。
主要发现
- 治疗12周后,司维拉姆组尿磷/肌酐比值较安慰剂组显著下降。
- 血清C端FGF23中位变化在安慰剂组为38(-13至114)RU/ml,司维拉姆组为37(-1至101)RU/ml,组间无显著差异(P=0.77)。
- 两组间血清完整FGF23、α-Klotho和血磷水平变化均无显著差异。
- 司维拉姆组血清总胆固醇和LDL胆固醇水平显著下降。
关键数值与推荐
- 基线平均eGFR为27±9 ml/min/1.73 m²,平均血磷为3.8±0.5 mg/dl,血清C端FGF23中位数(四分位距)为157(120-241)RU/ml。
- 司维拉姆剂量为4.8 g/日,治疗12周;所有患者随机时接受100,000 IU胆钙化醇。
临床怎么用
- 对于血磷正常的CKD 3b/4期患者,碳酸司维拉姆可降低尿磷排泄和血脂,但不降低血清FGF23或升高α-Klotho。
- 不应以降低FGF23为目的对血磷正常的CKD患者使用碳酸司维拉姆。
局限性
- 研究样本量较小(78例),干预时间仅12周。
- 所有患者均接受胆钙化醇,可能影响FGF23和Klotho的评估。
- 研究仅纳入血磷正常且C端FGF23>80 RU/ml的CKD 3b/4期患者,结果不能推广至其他CKD人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Epidemiologic studies suggest that higher serum phosphaturic hormone fibroblast growth factor 23 levels are associated with increase morbidity and mortality. The aim of the FGF23 Reduction Efficacy of a New Phosphate Binder in CKD Trial was to evaluate the effect of sevelamer carbonate on serum C-terminal fibroblast growth factor 23 levels in normophosphatemic patients with CKD stage 3b/4. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Patients with CKD, eGFR between 45 and 15 ml/min per 1.73 m2, fasting serum phosphate concentration >3.1 mg/dl, and serum C-terminal fibroblast growth factor 23 >80 relative units/ml were included in our double-blind, placebo-controlled, randomized multicenter study. All patients received 100,000 IU cholecalciferol at time of randomization. Participants received either placebo or sevelamer carbonate 4.8 g daily during a 12-week period. Biologic parameters, including serum C-terminal fibroblast growth factor 23, intact fibroblast growth factor 23, and α-klotho, were evaluated at baseline and 12 weeks after inclusion. RESULTS: Of 96 screened patients, 78 (mean±SD age: 63±13 years old; 70% men; mean eGFR: 27±9 ml/min per 1.73 m2) met the inclusion criteria. At baseline, mean eGFR was 27±9 ml/min per 1.73 m2, mean serum phosphate level was 3.8±0.5 mg/dl, and median (interquartile range) serum C-terminal fibroblast growth factor 23 level was 157 (120-241) relative units/ml. After 12 weeks of treatment, urinary phosphate-to-creatinine ratio fell significantly in the sevelamer group. The sevelamer and placebo groups did not differ significantly in terms of median change in serum C-terminal fibroblast growth factor 23 levels: the median (interquartile range) change was 38 (-13-114) relative units/ml in the placebo group and 37 (-1-101) relative units/ml in the sevelamer group (P=0.77). There was no significant difference in serum intact fibroblast growth factor 23, α-klotho, or phosphate levels changes between the two groups. Serum total and LDL cholesterol levels fell significantly in the sevelamer group. CONCLUSIONS: In our double-blind, placebo-controlled, randomized study performed in normophosphatemic patients with CKD, a 12-week course of sevelamer carbonate significantly reduced phosphaturia without changing serum phosphorus but did not significantly modify serum C-terminal fibroblast growth factor 23 and intact fibroblast growth factor 23 or α-klotho levels.
引用
- Liabeuf S, Ryckelynck JP, El Esper N, et al. Randomized Clinical Trial of Sevelamer Carbonate on Serum Klotho and Fibroblast Growth Factor 23 in CKD. Clin J Am Soc Nephrol. 2017. PMID: 29074818. doi:10.2215/CJN.03030317
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。